PD-L2 / Programmed death ligand 2 / CD273 Antibody from BIORBYT LTD.
Search, find, compare suppliers for anti-PD-L2 / Programmed death ligand 2 / CD273 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | PD-L2 / Programmed death ligand 2 / CD273 |
| Clone | PDL2/2676 |
| Host Species | Mouse |
| Reactive Species | human |
| Isotype | IgG1, kappa |
| Format | Protein G purified |
| Size | 100 ug, 20 ug |
| Concentration | n/a |
| Applications | ELISA, FACS, IF, WB |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Recognizes a protein identified as PD-L2 (same as PDCD1LG2). Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T cell proliferation, cytokine production, differentiation of effector T cells and the induction of Bcl-x, a promoter of T cell survival. Conversely, engagement of CTLA4 by B7-1 or B7-2 may inhibit proliferation and IL-2 production. PD-L2 does not bind CD28, cytotoxic T lymphocyte A4 or ICOS (inducible co-stimulator). The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the Pdcd-1-Pdcd-L system could provide unique negative signaling to help prevent autoimmune disease. |
| Immunogen | A recombinant fragment of human PD-L2 protein within amino acids 27-220 was used as the immunogen for the PD-L2 antibody. |
| Other Names | n/a |
| Gene, Accession # | UniProt: Q9BQ51 |
| Catalog # | orb607156 |
| Price | $764 |
| Order / More Info | PD-L2 / Programmed death ligand 2 / CD273 Antibody from BIORBYT LTD. |
| Product Specific References | n/a |
BIORBYT LTD.
BIORBYT LTD.
7 Signet Court
Swann Road
Cambridge, CB5 8LA U.K.
P: +44 (0)1223 859 353
F: +44(0)1223 280 240
info@biorbyt.com
http://www.biorbyt.com
U.S. OFFICE
Biorbyt LLC
1100 Corporate Square Drive
Helix Center, Suite 221
St Louis, MO 63132
Email: info@biorbyt.com
Phone: +1 (415) 906-5211
Fax: +1 (415) 651-8558
Profile of BIORBYT LTD.
Return to Antibodies